<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430052</url>
  </required_header>
  <id_info>
    <org_study_id>TatsuyaIoka</org_study_id>
    <secondary_id>UMIN000001990</secondary_id>
    <nct_id>NCT01430052</nct_id>
  </id_info>
  <brief_title>Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>Randomized Phase II Study Comparing Gemcitabine/S-1 Combination Chemoradiotherapy With Gemcitabine/S-1 Combination Chemotherapy for Unresectable Locally Advanced Pancreatic Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka Medical Center for Cancer and Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osaka Medical Center for Cancer and Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical effectiveness of Gemcitabine/S-1&#xD;
      combination chemoradiotherapy with Gemcitabine /S-1 combination chemotherapy for unresectable&#xD;
      locally advanced pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When cancer develops outside of the pancreas from within the anatomical placement of the&#xD;
      pancreas itself, it becomes difficult to excise in most cases. Generally, most pancreatic&#xD;
      cancers are already unresectable at the time of diagnosis when we have recognized&#xD;
      infiltration of over 1/2 the circumference of major arteries such as the celiac artery and&#xD;
      super mesenteric artery in particular.&#xD;
&#xD;
      In comparison with advanced pancreatic cancer with distant metastases, it is not easy to&#xD;
      treat unresectable locally advanced pancreatic cancer, even when performing standard&#xD;
      gemcitabine monotherapy. In the case of unresectable locally advanced pancreatic cancers&#xD;
      without distant metastases, we are left with the choice of whether or not to perform&#xD;
      radiation therapy. This decision remains unsolved worldwide, despite the continuing efforts&#xD;
      of researchers to bring an end to the clinical doubt.&#xD;
&#xD;
      We will report our results as well as the problems of combining treatments with&#xD;
      chemoradiotherapy, using the novel anticancer agent gemcitabine as well as/or S-1, not 5FU,&#xD;
      predominantly from our own clinical trials on this occasion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Two year survival rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival（PFS）</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine , S-1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Gemcitabine 1000mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine, S-1, radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine 600mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks with radiotherapy 50.4Gy in 28 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: gemcitabine, S-1</intervention_name>
    <description>Gemcitabine 1,000mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks.</description>
    <arm_group_label>Gemcitabine , S-1</arm_group_label>
    <other_name>gemzer</other_name>
    <other_name>TS-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine, S-1, radiotherapy</intervention_name>
    <description>Gemcitabine 600mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks. Concurrent radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions.</description>
    <arm_group_label>Gemcitabine, S-1, radiotherapy</arm_group_label>
    <other_name>gemzer</other_name>
    <other_name>TS-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed adenocarcinoma, adenocarcinoma squamous&#xD;
             carcinoma of pancreatic cancer.&#xD;
&#xD;
          2. Patients who confirmed unresectable locally advanced pancreatic cancer with the&#xD;
             criteria below.&#xD;
&#xD;
               -  Involving over 1/2 circumference of major artery (SMA/CA). (Under 1/2 that was&#xD;
                  borderline lesion.)&#xD;
&#xD;
               -  Involving over the merging section of portal-SMV.&#xD;
&#xD;
               -  No distal metastasis with diagnostic imaging.&#xD;
&#xD;
               -  Confirmed by CT image performed with in four weeks before registration.&#xD;
&#xD;
          3. Performance Status:0-1(ECOG)&#xD;
&#xD;
          4. Patients of age =&gt;20 and 80&gt;&#xD;
&#xD;
          5. sufficient organ functions&#xD;
&#xD;
               -  neutrophils&gt;=1,500/mm3&#xD;
&#xD;
               -  platelets&gt;=100,000/mm3&#xD;
&#xD;
               -  hemoglobin&gt;=9.0g/dl&#xD;
&#xD;
               -  AST(GOT)/ALT(GPT) &lt;=150IU&#xD;
&#xD;
               -  total bilirubin &lt;=2.0mg/dl, (or &lt;=3.0mg/dl if biliary drainage were present)&#xD;
&#xD;
               -  serum creatinine &lt;= 1.2mg/dl&#xD;
&#xD;
               -  creatinine clearance&gt;=60ml/min&#xD;
&#xD;
          6. Life expectancy more than 3 months.&#xD;
&#xD;
          7. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lung fibrosis or intestinal pneumonia, and anamnesis or imaging findings.&#xD;
&#xD;
          2. Watery diarrhea&#xD;
&#xD;
          3. Severe infection&#xD;
&#xD;
          4. Severe complication (heart failure, renal failure, hepatic insufficiency,hemorrhagic&#xD;
             peptic ulcer, intestines paralysis,ileus or uncontrolled diabetes etc)&#xD;
&#xD;
          5. Massive pleural or abdominal effusion.&#xD;
&#xD;
          6. Metastasis to central nervous system.&#xD;
&#xD;
          7. Active synchronous or metachronous malignancy other than carcinoma in situ.&#xD;
&#xD;
          8. Regular use of flucytosine, fenitoin or warfarin&#xD;
&#xD;
          9. Pregnant or lactation women, or women with known or suspected pregnancy and men who&#xD;
             want let to pregnancy&#xD;
&#xD;
         10. Severe mental illness&#xD;
&#xD;
         11. Patients who are judged inappropriate for the entry into the study by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatsuya Ioka, MD</last_name>
    <role>Study Director</role>
    <affiliation>Osaka Medical Center for Cancer and CVD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka</city>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>September 5, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>November 19, 2017</last_update_submitted>
  <last_update_submitted_qc>November 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Osaka Medical Center for Cancer and Cardiovascular Diseases</investigator_affiliation>
    <investigator_full_name>Tatsuya Ioka</investigator_full_name>
    <investigator_title>Assistant director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

